Fate therapeutics highlights positive durability of response data from ft516 phase 1 study for b-cell lymphoma and announces fda regenerative medicine advanced therapy designation granted to ft516 for relapsed / refractory dlbcl

6 of 10 patients naÏve to treatment with autologous car t-cell therapy continue in ongoing response at median follow-up of 9.1 months, including 4 patients with >6 months follow-up, at ≥90 million ft516 cells per dose
FATE Ratings Summary
FATE Quant Ranking